Literature DB >> 15944269

Positive and negative regulation of the IL-27 receptor during lymphoid cell activation.

Alejandro V Villarino1, Joseph Larkin, Christiaan J M Saris, Andrew J Caton, Sophie Lucas, Terence Wong, Frederic J de Sauvage, Christopher A Hunter.   

Abstract

Previous reports have focused on the ability of IL-27 to promote naive T cell responses but the present study reveals that surface expression of WSX-1, the ligand-specific component of the IL-27R, is low on these cells and that highest levels are found on effector and memory CD4(+) and CD8(+) T cells. Accordingly, during infection with Toxoplasma gondii, in vivo T cell activation is associated with enhanced expression of WSX-1, and, in vitro, TCR ligation can induce expression of WSX-1 regardless of the polarizing (Th1/Th2) environment present at the time of priming. However, while these data establish that mitogenic stimulation promotes expression of WSX-1 by T cells, activation of NK cells and NKT cells prompts a reduction in WSX-1 levels during acute toxoplasmosis. Together, with the finding that IL-2 can suppress expression of WSX-1 by activated CD4(+) T cells, these studies indicate that surface levels of the IL-27R can be regulated by positive and negative signals associated with lymphoid cell activation. Additionally, since high levels of WSX-1 are evident on resting NK cells, resting NKT cells, effector T cells, regulatory T cells, and memory T cells, the current work demonstrates that IL-27 can influence multiple effector cells of innate and adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944269     DOI: 10.4049/jimmunol.174.12.7684

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells.

Authors:  Nikhil S Joshi; Weiguo Cui; Claudia X Dominguez; Jonathan H Chen; Timothy W Hand; Susan M Kaech
Journal:  J Immunol       Date:  2011-09-19       Impact factor: 5.422

2.  Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection.

Authors:  James A Harker; Aleksandr Dolgoter; Elina I Zuniga
Journal:  Immunity       Date:  2013-08-29       Impact factor: 31.745

3.  The IL-27 receptor has biphasic effects in crescentic glomerulonephritis mediated through Th1 responses.

Authors:  Shaun A Summers; Richard K S Phoon; Joshua D Ooi; Stephen R Holdsworth; A Richard Kitching
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 4.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

5.  Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice.

Authors:  Miranda L Hanson; Julie A Hixon; Wenqing Li; Barbara K Felber; Miriam R Anver; C Andrew Stewart; Brian M Janelsins; Sandip K Datta; Wei Shen; Mairi H McLean; Scott K Durum
Journal:  Gastroenterology       Date:  2013-10-09       Impact factor: 22.682

6.  Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response.

Authors:  Georgia Perona-Wright; Jacob E Kohlmeier; Elizabeth Bassity; Tori C Freitas; Katja Mohrs; Tres Cookenham; Haozhong Situ; Edward J Pearce; David L Woodland; Markus Mohrs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

Review 7.  Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature.

Authors:  Caroline Andrews; Mairi H McLean; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

8.  Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Authors:  Rosalba Salcedo; Julie A Hixon; Jimmy K Stauffer; Rashmi Jalah; Alan D Brooks; Tahira Khan; Ren-Ming Dai; Loretta Scheetz; Erin Lincoln; Timothy C Back; Douglas Powell; Arthur A Hurwitz; Thomas J Sayers; Robert Kastelein; George N Pavlakis; Barbara K Felber; Giorgio Trinchieri; Jon M Wigginton
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  Distinct response of liver myeloid dendritic cells to endotoxin is mediated by IL-27.

Authors:  Yun Chen; Guoping Jiang; Horng-Ren Yang; Xiaodong Gu; Lianfu Wang; Ching-Chuan Hsieh; Hong-Shiue Chou; John J Fung; Shiguang Qian; Lina Lu
Journal:  J Hepatol       Date:  2009-06-13       Impact factor: 25.083

Review 10.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.